Alector Highlights Mid-Stage Study Data On Lead Dementia Drug - Alector (NASDAQ:ALEC)

Alector Inc (NASDAQ:ALEC) is flashing some AL001 (latozinemab) Phase 2 data at an Alzheimer’s and Parkinson’s disease conference, this time in dementia with a different type of mutation: C9orf72.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Results in this cohort also showed elevated progranulin levels in both plasma and cerebrospinal fluid while patients were on monthly treatment for a year.
Additionally, clinical assessments showed a delay in annualized disease progression, approximately 54%.
Related: Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients.
Mean levels of neurofilament light chain (NfL), a marker of axonal damage, remained stable over the course of treatment in both plasma and CSF in latozinemab-treated FTD-C9orf72 patients.
Mean levels of glial fibrillary acidic protein (GFAP), a biomarker of astrogliosis that indicates disease and/or injury to the central nervous system, decreased over 12 months in both plasma and CSF in latozinemab-treated FTD-C9orf72 patients.
Price Action: ALEC shares are down 2.33% at $13.20 during the market session on the last check Tuesday.

ALECAlector Inc

$2.148.08%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.